The present invention relates to a solid oral pharmaceutical composition comprising an effective amount of Esciicarbazepine or its pharmaceutical acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The invention also relates to a process for the preparation of a pharmaceutical composition comprising an effective amount of Esciicarbazepine, wherein the composition is manufactured by extrusion-spheronization technique. The prior art highlights challenges of Eslicarbazepine during formulation development with convention granulation techniques. The manufacturing process employed in the present invention involves a simple, dust free, reproducible, and commercially viable process.
